Literature DB >> 18686017

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Jae Eun Ahn1, Mats O Karlsson, Adrian Dunne, Thomas M Ludden.   

Abstract

PURPOSE: To evaluate the likelihood-based methods for handling data below the quantification limit (BQL) using new features in NONMEM VI.
METHODS: A two-compartment pharmacokinetic model with first-order absorption was chosen for investigation. Methods evaluated were: discarding BQL observations (M1), discarding BQL observations but adjusting the likelihood for the remaining data (M2), maximizing the likelihood for the data above the limit of quantification (LOQ) and treating BQL data as censored (M3), and like M3 but conditioning on the observation being greater than zero (M4). These four methods were compared using data simulated with a proportional error model. M2, M3, and M4 were also compared using data simulated from a positively truncated normal distribution. Successful terminations and bias and precision of parameter estimates were assessed.
RESULTS: For the data simulated with a proportional error model, the overall performance was best for M3 followed by M2 and M1. M3 and M4 resulted in similar estimates in analyses without log transformation. For data simulated with the truncated normal distribution, M4 performed better than M3.
CONCLUSIONS: Analyses that maximized the likelihood of the data above the LOQ and treated BQL data as censored provided the most accurate and precise parameter estimates.

Mesh:

Year:  2008        PMID: 18686017     DOI: 10.1007/s10928-008-9094-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  5 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  Derivation of various NONMEM estimation methods.

Authors:  Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-10       Impact factor: 2.745

5.  An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

Authors:  J Wakefield; A Racine-Poon
Journal:  Stat Med       Date:  1995 May 15-30       Impact factor: 2.373

  5 in total
  146 in total

1.  Extending the latent variable model for extra correlated longitudinal dichotomous responses.

Authors:  Matthew M Hutmacher; Jonathan L French
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-22       Impact factor: 2.745

2.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

3.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

4.  Use of pharmacokinetic data below lower limit of quantitation values.

Authors:  William J Jusko
Journal:  Pharm Res       Date:  2012-06-23       Impact factor: 4.200

5.  Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.

Authors:  Todd A Riccobene; Richard Pushkin; Alena Jandourek; William Knebel; Tatiana Khariton
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.

Authors:  Belén P Solans; Angèle Fleury; Matthias Freiwald; Holger Fritsch; Karin Haug; Iñaki F Trocóniz
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

7.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

8.  Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.

Authors:  Yanhui Lu; Vineet Goti; Ayyappa Chaturvedula; Jessica E Haberer; Michael J Fossler; Mark E Sale; David Bangsberg; Jared M Baeten; Connie L Celum; Craig W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

10.  Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Authors:  Celine M Laffont; Roberto Gomeni; Bo Zheng; Christian Heidbreder; Paul J Fudala; Azmi F Nasser
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.